Join to View Full Profile
Dept Dermatology, Perelman School of Medicine at Univ Pennsylvania3400 Civic Center BlvdPhiladelphia, PA 19104
Phone+1 215-662-2737
Fax+1 215-615-4966
Dr. Kim is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Ellen J. Kim is a board certified dermatologist and Professor of Dermatology at the Perelman School of Medicine at the University of Pennsylvania. She is currently the Director of the Penn Cutaneous Lymphoma Program/Photopheresis Service and Vice Chair of Clinical Operations for the Department of Dermatology. She is an international expert in the diagnosis and multidisciplinary clinical care of patients with cutaneous lymphomas and the use of extracorporeal photopheresis. Her primary research focus is clinical trials of novel therapies for cutaneous T-cell lymphoma (CTCL).
Education & Training
Boston University Medical CenterResidency, Dermatology, 1997 - 2000
Perelman School of Medicine at the University of PennsylvaniaClass of 1996
Certifications & Licensure
PA State Medical License 2002 - 2026
NJ State Medical License 2022 - 2025
MA State Medical License 1998 - 2003
American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- Leonard Berwick Memorial Teaching Award Perelman School of Medicine at the University of Pennsylvania, 2014
- Inaugural Class, The Academy of Master Clinicians Penn Medicine, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Join now to see all
Clinical Trials
- Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Start of enrollment: 2012 Nov 01
Publications & Presentations
PubMed
- Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome.Omar Elghawy, Jonathan H Sussman, Austin G Yang, Colin J Thomas, Jordan S Carter
JAMA Dermatology. 2025-04-02 - Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome.Omar Elghawy, Austin G Yang, Jonathan H Sussman, Colin J Thomas, Jordan S Carter
Journal of the American Academy of Dermatology. 2025-03-01 - Black patients with Mycosis fungoides and Sézary Syndrome experience worse health-related quality of life: A cross-sectional study.Anise Marshall, Shamey Kassim, Jessica Brown-Korsah, Caroline Raymundo, Corey Chang
Journal of the American Academy of Dermatology. 2025-01-10
Journal Articles
- Brentuximab Vedotin for Relapsed or Refractory Sézary SyndromePaul L Haun, Sara S Samimi, Alain H Rook, Ellen J Kim, JAMA Dermatology
- Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of Sézary SyndromeEllen J Kim, Carmela Vittorio, Paul L Haun, Sara S Samimi, Rachael A Clark, Alain H Rook, JAMA Dermatology
Press Mentions
Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-cell LymphomaDecember 16th, 2024- HyBryte™ Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer ConferenceOctober 7th, 2024
- New PDT Therapy for CTCL to Be Reviewed by FDADecember 22nd, 2022
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
